热门资讯> 正文
Rigel就其免疫性血小板减少症治疗的专利诉讼达成和解
2025-03-27 21:59
- Rigel制药(RIGL) 0
- stem(STEM) 0
- 劳氏(LOW) 0
- Rigel Pharmaceuticals (RIGL) announced a settlement agreement with Annora Pharma Private, Hetero Labs, and Hetero USA, resolving an ongoing patent dispute related to TAVALISSE, the company's treatment for chronic immune thrombocytopenia.
- As part of the agreement, Annora has been granted a license to sell its generic version of TAVALISSE starting in Q2 2032, or earlier under specific conditions.
- The litigation stemmed from Annora’s submission of an Abbreviated New Drug Application to the U.S. FDA, seeking approval to market a generic version of TAVALISSE in the United States.
- With this settlement, the company said that all ongoing legal proceedings between Rigel and Annora regarding TAVALISSE patents in New Jersey have been dismissed.
More on Rigel Pharmaceuticals
- Rigel Looks Interesting, But Let's Wait For A Lower Price
- Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript
- Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents
- Rigel Pharmaceuticals appoints Mark W. Frohlich to board of directors
- Rigel Pharmaceuticals sets 2025 sales outlook above estimates
推荐文章
一周财经日历丨降息信号将定？下周全球央行年会成关键；小米、泡泡玛特、快手领衔港股财报潮
港股周报丨见证历史！南向资金单日疯狂买入港股359亿港元；腾讯绩后股价一度升破600港元
特朗普政府据悉考虑动用芯片法案资金来入股英特尔
美股机会日报丨“恐怖数据”符合预期，交易员下调美联储降息预期；巴菲特Q2新建仓股飙升，联合健康盘前涨超10%
银诺医药-B上市首日暴涨285%，一手赚超1万港元
投资大佬Tepper减持阿里巴巴、京东等 买入股价暴跌的联合健康
伯克希尔减持苹果股份 增持联合健康集团
8月15日外盘头条：特朗普政府洽购英特尔股份 贝森特否认推动降息 苹果重新设计Apple Watch血氧功能
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
